AGIO logo

AGIOAgios Pharmaceuticals Inc

$28.88
$0.74
(2.58%)
Today
Closed $29.46
$0.58
(1.97%)
After Hours
Updated: 05:11 PM EDT
EarningsJul 30
Mkt Cap$1.75B
Vol1.14M
News
all
press releases
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Zacks
News Placeholder
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
Zacks
News Placeholder
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.
Zacks
News Placeholder
Avanzanite Biosciences Partner Agios Announces PYRUKYND (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts...
Business Wire
News Placeholder
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
Zacks
News Placeholder
Agios Files FDA Application Seeking Accelerated Approval Of Mitapivat For Sickle Cell Disease
(RTTNews) - Rare disease drugmaker Agios Pharmaceuticals Inc. (AGIO) on Tuesday announced the submission of a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration...
Nasdaq News: Markets
News Placeholder
HC Wainwright Issues Positive Outlook for AGIO Earnings
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued on Wednesday, April 29th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical compa...
MarketBeat
News Placeholder
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
Key PointsAgios shares rose after strong earnings and Aqvesme's commercial launch...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.